The transactions highlighted below are representative of Greenhill engagements. In addition, the Firm has completed many engagements that were not publicly-disclosed.
Recent Transactions
Sort By
Concordia International Corp.
Advised an Ad Hoc Group of Cross-over Debtholders on Concordia International’s cross-border Canadian restructuring and recapitalization, including a US$586.5mm common equity private placement, the equitization of ~US$1.7bn of unsecured debt and the partial paydown and exchange of ~US$2.2bn of secured debt
IslaLink
Advised EQT, a leading alternative investments firm with more than EUR 37 billion of AUM on the sale of its portfolio company IslaLink, a leading neutral and independent submarine fiber infrastructure operator in the Balearic Islands
Cityfibre Infrastructure Holdings plc
Advised Antin Infrastructure Partners and West Street Infrastructure Partners, part of Goldman Sachs’ Merchant Banking division, in connection with the take private of CityFibre Infrastructure Holdings plc, a leading independent provider of wholesale fibre network infrastructure
Novartis AG’s 36.5% stake in Consumer Health Joint Venture
Advised and acted as sponsor to GlaxoSmithKline plc, the UK’s leading pharmaceutical company, on the buyout of Novartis’ 36.5% stake in their Consumer Health Joint Venture
Midwest Television, Inc.
Advised TEGNA, Inc., a major broadcasting and digital marketing services company, on the acquisition of Midwest Television, Inc.
MorphoSys AG
Advised MorphoSys AG, a German biopharmaceutical company, on a regional licensing agreement covering Greater China and comprising its investigational anti-CD38 antibody MOR202 targeting multiple myeloma, with I-Mab
Hirslanden Private Hospital Group
Advised Hirslanden Private Hospital Group, Switzerland's largest private hospital group and a wholly-owned subsidiary of Mediclinic International Plc, on the refinancing of its CHF 2.0 billion senior secured bank debt
Radiogroup Participações S.A.
Advised Radiogroup, a regional leader in cancer treatment through radiotherapy, on its sale of a majority stake to Grupo Oncoclínicas
CareerBuilder, LLC
Advised TEGNA, Inc., a leading broadcasting company, on the sale of its 53% ownership stake in CareerBuilder, LLC for $250 million of cash proceeds and 12.5% ongoing ownership
F+W Media
Advised F+W Media, a content and e-commerce company focused on a variety of special interest categories, on the out-of-court restructuring of its c.$100 million term loan and a $15 million new money investment from existing lenders
Equity stake in Bupa Arabia
Advised Bupa, a leading international healthcare group, on the increase of its stake in Bupa Arabia, one of the largest health insurance providers in the Kingdom of Saudi Arabia
Ad Hoc Group of Senior Secured Noteholders
Advised the Ad Hoc Group of Senior Secured Noteholders in connection with the restructuring of Goodman Networks.
Derma Sciences, Inc.
Advised Derma Sciences, Inc., a tissue regeneration company focused on advanced wound and burn care, on its sale to Integra LifeSciences Holdings Corporation, a global leader in medical technology
Palatin Technologies, Inc. lead product candidate, Rekynda
Advised Palatin Technologies, Inc. on the exclusive licensing of North American rights to develop and commercialize RekyndaTM (bremelanotide), an investigational product designed for on-demand treatment for hypoactive sexual desire disorder in pre-menopausal women, to AMAG Pharmaceuticals, Inc.
Host Europe Group
Advised GoDaddy, the largest domain name registrar worldwide and a leading web hosting provider, on its acquisition of Host Europe Group, the largest privately owned web services provider in Europe
Portfolio of 119 marketed and development pipeline products from Teva Pharmaceutical Industries Ltd.
Advised Teva Pharmaceutical Industries Ltd., the world’s largest generic drug company, on the divestment of a portfolio of 119 marketed and development pipeline products to Rivopharm SA
Portfolio of generic marketed products in France from Teva Pharmaceutical Industries Ltd.
Advised Teva Pharmaceutical Industries Ltd., the world’s largest generic drug company, on the divestment of a portfolio of generic marketed products in France to Arrow Generiques SAS (a subsidiary of Aurobindo Pharma Limited).
Adams Media
Advised F+W Media, a content and e-commerce company, on the divestment its consumer book publishing business, Adams Media, to Simon & Schuster, a division of CBS Corporation
IAC/InterActiveCorp
Advised the Special Committee of the Board of Directors of IAC/InterActiveCorp, a leading media and internet company, on the potential creation of a new class of non-voting common stock
Concordia International Corp
Advised the Special Committee of the Board of Directors of Concordia International, a diverse, international specialty pharmaceutical company focused on generic and legacy pharmaceutical products and orphan drugs, on its strategic review process
Assets and operations of Actavis Generics in the UK and Ireland from Teva Pharmaceutical Industries Ltd.
Advised Teva Pharmaceutical Industries Ltd., the world’s largest generic drug company, on its sale of assets and operations of Actavis Generics in the UK and Ireland to Accord Healthcare Ltd. (a subsidiary of Intas Pharmaceuticals Limited) for £603m (c.$775m)
Portfolio of 14 Outlicensing generic products in the EEA from Teva Pharmaceutical Industries Ltd.
Advised Teva Pharmaceutical Industries Ltd., the world’s largest generic drug company, on the divestment of a portfolio of 14 Outlicensing pharmaceutical products in the EEA to Accord Healthcare Ltd. (a subsidiary of Intas Pharmaceuticals Limited).
US rights to Toprol-XL (AstraZeneca)
Advised Aralez Pharmaceuticals Inc., a global specialty pharmaceutical company in connection with the financing of its acquisition of the US rights to cardiovascular drug Toprol-XL (metoprolol succinate) and its Authorized Generic from AstraZeneca.
TEGNA, Inc.
Advised TEGNA, Inc., a major broadcasting and digital marketing services company, on the spin-off of Cars.com and the creation of two independent publicly traded companies: one focused on television broadcasting and one focused on the online automotive marketplace.
Bionomics Limited
Advised ASX-listed Bionomics, a clinical stage biopharmaceutical company focused on the treatment of serious central nervous system disorders and cancer, on a consultation process with shareholders following calls for Board change, leading to the formation of a shareholder working group of leading institutional investors and company-led Board renewal.